top of page
Newsroom
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business combination with Breeze Holdings Acquisition Corp. (“Breeze”), a publicly traded special purpose acquisition company.
Aug 29, 2025
Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited
IRVING, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) — Breeze Holdings Acquisition Corp . (OTCQX: BRZH, BRZHR, BRZHW), a publicly traded...
Sep 25, 2024
3D Global Biotech and YD Biopharma Forge Strategic Partnership to Drive Biotech Innovation
On June 19, 2024, 3D Global Biotech announced a significant patent licensing agreement with its major shareholder, YD Biopharma. The...
Jun 19, 2024
bottom of page